• China’s NMPA cleared Takeda’s ORZEYFUL (oveporexton) to treat narcolepsy type 1 in patients aged 16+.
• Drug is the first oral OX2R-selective orexin agonist approved in China, positioning it as a new mechanism-based option for NT1.
• US filing is under priority review with Breakthrough Therapy designation; Japan review is ongoing with Sakigake designation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein.